Adrenal Medullary Hyperplasia: A Systematic Review and Meta-analysis  Journal of Clinical Endocrinology and Metabolism. 2023;108(9):e885-e892
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=36896586

Antidepressant use during pregnancy and the risk for gestational diabetes: a systematic review and meta-analysis  Journal of Maternal-Fetal & Neonatal Medicine. 2023;36(1):2162817
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=36599445

Anti-Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia  New England Journal of Medicine. 2023;389(8):767-769
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37611129

Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis  Gynecological Endocrinology. 2023;39(1):2152790
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=36480935

Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review  Genes (Basel). 2023;14(8)
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37628624

CagriSema and the link between obesity and type 2 diabetes  Lancet. 2023;402(10403):671-673
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37364591

Coordinated Care for Optimization of Cardiovascular Preventive Therapies in Patients With Diabetes  JAMA. 2023;330(8):771
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37606678

Craniopharyngioma-An update on metabolic and cognitive complications and new therapy  Journal of Internal Medicine. 2023;294(3):269-280
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37424210

Diabetes: Doctors are told not to start new patients on GLP-1 agonists because of shortages  BMJ. 2023;382:p2019
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37657814

DMF scores in patients with diabetes mellitus: A systematic review and meta-analysis of observational studies  Journal of Dentistry. 2023;136:104628
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37490966

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial  Lancet. 2023;402(10403):720-730
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37364590

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial  Lancet. 2023;402(10403):693-704
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385279

Efficacy and safety of PCSK9 inhibitors in patients with diabetes: A systematic review and meta-analysis  Nutrition, Metabolism, and Cardiovascular Diseases. 2023;33(9):1647-1661
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37414664

The experiences and barriers in addressing type 2 diabetes mellitus-associated erectile dysfunction: a mixed method systematic review  Syst Rev. 2023;12(1):138
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37563662

Models Predicting Postpartum Glucose Intolerance Among Women with a History of Gestational Diabetes Mellitus: a Systematic Review  Current Diabetes Reports. 2023;23(9):231-243
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37294513

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena  Lancet. 2023;402(10401):504-505
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385276

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial  Lancet. 2023;402(10403):705-719
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385278

Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists  JAMA. 2023;330(7):650-657
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37505513

Patient Portals as Facilitators of Engagement in Patients With Diabetes and Chronic Heart Disease: Scoping Review of Usage and Usability  Journal of Medical Internet Research. 2023;25:e38447
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37624629

Prevalence of impaired awareness of hypoglycaemia in people with diabetes mellitus: A systematic review and meta-analysis from 21 countries and regions  Diabetic Medicine. 2023;40(9):e15129
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37143390

The pursuit of optimal semaglutide dosing in type 2 diabetes continues  Lancet. 2023;402(10403):668-669
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385277

Relationship between dyslipidemia and diabetic retinopathy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis  Syst Rev. 2023;12(1):148
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37620980

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA  Lancet. 2023;402(10401):529-544
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385280

SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide  Lancet. 2023;402(10402):586-588
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385274

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial  Lancet. 2023;402(10402):613-626
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=37385275